“John’s appointment is the culmination of a rigorous and thoughtful search process over the past six months,” says board chair, Craig Baxter. “We believe he is the ideal CEO for the Company. He is a visionary leader and strong manager who brings a successful track record of growing companies and efficiently managing them to create value for shareholders, customers, partners and employees.” [Click on Logo to learn more]
News Archive: Cangene
“This is an extremely positive step. Not only does this significantly increase the total revenue value of this contract, it also indicates that BARDA is adopting a strategy of extending these types of contracts to replenish supplies of biodefence products. As the supplier for three products in the U.S. Strategic National Stockpile, that’s an indication we are happy to see,” said Michael Graham, acting President and CEO of Cangene. [Click on Logo to learn more]
Cangene Announces Second Quarter Financial Results for Fiscal 2011, Which Have Been Prepared In Accordance With IFRS
Revenues for the second quarter of 2011 were US$40.2 million, 3% higher than the US$39.0 million recorded during the same period last year. Two deliveries on U.S. government biodefence contracts during the current quarter contributed to the strong revenue. [Click on Pic to learn more]
Cangene announces that it has received approval from the Canadian securities regulatory authorities to prepare its financial statements in accordance with International Financial Reporting Standards (“IFRS”) for financial reporting periods beginning on or after January 1, 2010, one year ahead of the mandatory conversion date for Canadian public companies. [Click on Logo to learn more]
Effective immediately, Dr. Langstaff resigns from his position as President and CEO, and from the Board of Directors, but will continue as a special advisor to the Company. [Click on Logo to learn more]
“This change builds upon our strategy to strengthen our corporate brand in all our markets and for all our stakeholders. We had rebranded our plasma-centre operations as Cangene Plasma Resources; this reorganization formalizes the change and streamlines our corporate structure,” said Dr. John Langstaff, president and CEO of Cangene Corporation. [Click on Logo to learn more]
“Our financial performance in 2010 reflects our investment in change that adds a new dimension to our business as we have brought our U.S. sales and marketing in-house for the first time in our history. We have also invested in pipeline development, particularly with respect to IGIV, a widely used anti-infective product that we believe will be a good complement to our hospital-based commercial product line-up. Our solid cash and debt-free position allowed us these opportunities to invest in our future growth,” said Dr. John Langstaff, president and CEO of Cangene. [Click on Logo to learn more]
“This approval extends the reach of this product, which is our second largest selling commercial product in North America where it has two approved indications. While this market is relatively small compared with North America, this is nevertheless a positive development,” said Dr. John Langstaff, Cangene’s president and CEO. [Click on Logo to learn more]
“This is another positive regulatory step for this product, which is our second largest commercial product in North America where it has two approved indications” said Dr. John Langstaff, Cangene’s president and CEO. [Click on Logo to learn more]
“The financial results for the quarter continue to reflect our delivery on the biodefence contracts in accordance with established schedules,” said Dr. John Langstaff, Cangene’s president and CEO. “We have also begun to focus more directly on the U.S. commercial markets, beginning with our acquisition of the U.S. commercialization rights for HepaGam B(R) from Apotex. [Click on Logo to learn more]
A world leader in the development , manufacture, and commercialization of specialty hyperimmune plasma and biotechnology products.
Premier Gary Doer is promoting Manitoba as a major hub of knowledge, research and innovation at the 2009 BIO International Conference, where he is leading a delegation that includes more than 30 leaders from the province’s life-sciences industry, research and post-secondary education sectors.